Biofabrication and biomanufacturing in Ireland and the UK

Jack F. Murphy, Martha Lavelle, Lisa Asciak, Ross Burdis, Hannah J. Levis, Cosimo Ligorio, Jamie McGuire, Marlene Polleres, Poppy O. Smith, Lucinda Tullie, Juan Uribe-Gomez, Biqiong Chen, Jonathan I. Dawson, Julien E. Gautrot, Nigel M. Hooper, Daniel J. Kelly, Vivian S. W. Li, Alvaro Mata, Abhay Pandit, James B. PhillipsWenmiao Shu, Molly M. Stevens, Rachel L. Williams, James P. K. Armstrong*, Yan Yan Shery Huang*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

3 Citations (Scopus)
9 Downloads (Pure)

Abstract

As we navigate the transition from the Fourth to the Fifth Industrial Revolution, the emerging fields of biomanufacturing and biofabrication are transforming life sciences and healthcare. These sectors are benefiting from a synergy of synthetic and engineering biology, sustainable manufacturing, and integrated design principles. Advanced techniques such as 3D bioprinting, tissue engineering, directed assembly, and self-assembly are instrumental in creating biomimetic scaffolds, tissues, organoids, medical devices, and biohybrid systems. The field of biofabrication in the United Kingdom and Ireland is emerging as a pivotal force in bioscience and healthcare, propelled by cutting-edge research and development. Concentrating on the production of biologically functional products for use in drug delivery, in vitro models, and tissue engineering, research institutions across these regions are dedicated to innovating healthcare solutions that adhere to ethical standards while prioritising sustainability, affordability, and healthcare system benefits.
Original languageEnglish
Pages (from-to)825-856
Number of pages32
JournalBio-Design and Manufacturing
Volume7
Issue number6
Early online date23 Oct 2024
DOIs
Publication statusPublished - 1 Nov 2024

Funding

JFM is supported by the W.D. Armstrong Trust. YYSH is funded by the European Research Council (ERC-StG, 758865) and the UK Research and Innovations (UKRI) Biotechnology and Biological Sciences Research Council (BB/W014564/1). JPKA acknowledges funding from a UKRI Future Leaders Fellowship (MR/V024965/1). POS is supported by the BBSRC London Interdisciplinary Doctoral (LIDo) Programme. WS and LA acknowledge the funding support of EPSRC (EP/W004860/1, EP/X033686/1) and MRC (MR/V029827/1, MR/W030381/1). JEG thanks the European Research Council (ProLiCell, 772462) for support. CL and AM thank the NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham, UK and the AO Foundation, AO CMF (AOCMF-21-04S). AO CMF is a clinical division of the AO Foundation — an independent medically guided not-for-profit organization. HJL acknowledges funding support from grant MR/W01470X/1. BC thanks the EPSRC (EP/W018977/1) for financial support. RB and MMS acknowledge funding from the EPSRC (EP/T020792/1). AP and JUG acknowledge funding from BiomatDB+ (Horizon Europe 101058779) and acknowledge funding received from Science Foundation Ireland (SFI)—Grant No. 13/RC/2073_P2.

Keywords

  • Sustainability
  • Tissue engineering
  • Drug delivery
  • Biohybrid
  • Bioprinting
  • Biomaterials

Fingerprint

Dive into the research topics of 'Biofabrication and biomanufacturing in Ireland and the UK'. Together they form a unique fingerprint.

Cite this